Related Experiment Video

Updated: Jul 16, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating

Mao Li1, Zhuo Zhang, Donald L Hill

  • 1Department of Pharmacology and Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 32594, USA.

Cancer Research
|March 3, 2007
PubMed

Insights

Curcumin inhibits the MDM2 oncogene, a key target in cancer therapy. This novel mechanism, independent of p53, shows promise for both cancer prevention and treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • MDM2 is an oncoprotein and a ubiquitin E3 ligase for tumor suppressor p53, making it a potential cancer therapy target.
  • Curcumin, known for its anticancer properties, was investigated for its effects on MDM2 expression.

Purpose of the Study:

  • To determine if curcumin inhibits MDM2 expression.
  • To elucidate the mechanism of curcumin's action on MDM2 and its impact on cancer cells.

Main Methods:

  • Investigated curcumin's effect on MDM2 protein and mRNA levels in human prostate cancer cells (PC3).
  • Assessed the role of the PI3K/mTOR/ETS2 pathway in curcumin's inhibitory effects.
  • Evaluated curcumin's impact on cancer cell apoptosis, proliferation, and response to chemotherapy in vitro and in vivo.

Main Results:

  • Curcumin down-regulated MDM2 expression at both protein and mRNA levels in a dose- and time-dependent manner, independent of p53.
  • Curcumin enhanced the expression of the tumor suppressor p21(Waf1/CIP1).
  • Curcumin inhibited PC3 cell proliferation and induced apoptosis, effects that were modulated by MDM2 levels. Curcumin also enhanced gemcitabine efficacy and inhibited tumor growth in vivo.

Conclusions:

  • Curcumin's down-regulation of the MDM2 oncogene is a novel mechanism contributing to its chemopreventive and chemotherapeutic effects.
  • This action, independent of p53, provides a new understanding of curcumin's anticancer activity.
  • Curcumin represents a potential therapeutic agent for cancer, targeting MDM2 expression.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...